AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03165877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Subjects ate standard lunches and dinners (>60%),consisting of salad, main course and dessert, respectively.
Study NCT00563680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
Study NCT01801683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention-using PEARLS
Description: The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
Study NCT03352895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: Grape seed extract 100mg Microcrystalline Cellulose 90mg Magnesium Stearate 2mg Gelatin 100mg
Study NCT03352895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
Study NCT01060475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIM-0705 and tacrolimus
Description: Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
Study NCT01060475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIM-0705 and tacrolimus
Description: Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
Study NCT01060475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo LIM-0705 and tacrolimus
Description: Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
Study NCT01060475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug LIM-0705 and placebo tacrolimus
Description: Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
Study NCT03032861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
Study NCT02408328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Loading dose and continues use of caffeine until 44 weeks postmenstrual age
Study NCT02408328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home monitor
Description: Use of home monitor until 44 weeks postmenstrual age
Study NCT02408328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continued inpatient monitoring until apnea resolution
Description: Continued inpatient monitoring until apnea resolution
Study NCT00377936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine alone
Description: Gemcitabine monotherapy 1000 mg/m2 weekly
Study NCT00377936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1 and Gemcitabine
Description: EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
Study NCT03777696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: 1 gm of tranexamic acid in 100 ml saline iv
Study NCT03777696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TA
Description: 1 gm of tranexamic acid in 100 ml saline iv
Study NCT03777696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to misoprostol
Description: placebo tablets to misoprostol buccal
Study NCT00377936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1 and Gemcitabine
Description: EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
Study NCT00377936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1 and Gemcitabine
Description: EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
Study NCT01200940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: sucralose will be given at doses of 68 mg (equivalent to one 12 oz soda) 170 mg (equivalent to two and one-half 12 oz sodas, and 250 mg (equal to 100% of the FDA s acceptable daily intake for a 50kg individual).
Study NCT01200940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspartame
Description: To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
Study NCT01200940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acesulfame-Potassium
Description: To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
Study NCT03777696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: 110 ml saline iv
Study NCT01200940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
Study NCT02635581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta TT acetabular cup
Study NCT04765527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric Strength for Joint
Description: Turmeric-based tablets
Study NCT04765527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT01893645 — intervention group
Intervention type: DEVICE
Intervention: Pronto-7
Description: A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
Study NCT03776292 — intervention group
Intervention type: OTHER
Intervention: monitoring
Description: Primary outcome; composite 1ry outcome \[1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring\] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)\] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.
Study NCT00826579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node procedure
Description: After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
Study NCT00826579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
Study NCT01817192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
Study NCT01817192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiographic surveillance
Description: Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.
Study NCT01817192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14-Gene Prognostic Assay
Description: This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
Study NCT04803188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance
Description: Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.~All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy.
Study NCT03612739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 CAR-T Cells
Description: The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5.
Study NCT00355472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: IV administration at 4 escalating dose levels.
Study NCT03848247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of Isotonic saline
Description: Half the participants will be injected in a neck muscle with isotonic saline (Control group) and the other half will get NGF (Neck pain group).
Study NCT03848247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of NGF
Description: Half the participants will be injected in a neck muscle with NGF (Neck pain group).
Study NCT02293291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Water
Description: To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI
Study NCT02293291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lithium Water
Description: To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI
Study NCT02217631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 BS H3PO4
Study NCT02217631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone low dose
Study NCT03747744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD1c (BDCA-1)+ myDC
Description: Intratumoral injection in subcutaneous, cutaneous, soft tissue metastases
Study NCT01701219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ceftaroline fosamil
Description: Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
Study NCT02217631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone high dose
Study NCT02217631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00653484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Study NCT00653484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Study NCT00653484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity and Energy Restriction
Study NCT02196740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste
Description: Pulp removal,Root canal irrigation and disinfection,
Study NCT02196740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: creosote
Description: Pulp removal,Root canal irrigation and disinfection
Study NCT01277718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
Study NCT01277718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
Study NCT05173246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 240mg, ivdrip, d1, Q3w
Study NCT05173246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w
Study NCT05173246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m2, ivdrip,d1,Q3w
Study NCT05173246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5,d1,Q3w
Study NCT01758055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MSCs transplantation
Description: Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
Study NCT03646357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-betablocker
Description: No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.
Study NCT03646357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betablocker
Description: A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be:~* Metoprolol succinate up to a total dose of 200mg daily~* Bisoprolol up to a total dose of 10mg daily~* Carvedilol up to a total dose of 50mg daily~The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care.
Study NCT00373373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 2 x 400 mg/d
Study NCT00373373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Chemotherapy + Placebo
Study NCT02359565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF and blood sample collection
Study NCT02359565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Magnetic Resonance Imaging
Description: Undergo standard MRI
Study NCT02359565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging
Description: Undergo DTI
Study NCT02359565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo MR diffusion imaging
Study NCT02359565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-enhanced MR Perfusion
Description: Undergo DCE permeability MRI
Study NCT02359565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging
Description: Undergo DSC perfusion MRI
Study NCT02359565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MR spectroscopy
Study NCT02359565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03721822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
Study NCT03110965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga poses
Description: Patients are asked to perform one or two yoga poses daily for 4-10 months
Study NCT03279861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto
Description: First line therapy in Entresto arm
Study NCT03279861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: First line therapy in usual meds arm
Study NCT00933426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
Study NCT00933426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m\^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
Study NCT04446598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-ablative SMOOTH mode Erbium YAG laser
Description: Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode
Study NCT04446598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: oral tadalafil 5 mg was administered daily over a period of two months
Study NCT01582646 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Terbutaline sustained release 5 mg
Description: Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
Study NCT02881203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe Well
Description: Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
Study NCT02881203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RPM
Description: Varian Real-time Position Management (RPM) system
Study NCT03190226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF membranes
Description: split-mouth design, randomized L-PRF membranes vs. free gingival graft
Study NCT02881203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RPM
Description: Varian Real-time Position Management (RPM) system
Study NCT03190226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft
Description: split-mouth design, randomized L-PRF membranes vs. free gingival graft
Study NCT00380276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MPC-7869
Description: 800 mg BID Oral dosing
Study NCT00765128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.